Twitter Digest for January 26, 2018

Twitter Digest for January 25, 2018

Twitter Digest for January 24, 2018

Twitter Digest for January 23, 2018

Spotlight on Pregnancy and epilepsy

Approximately 20,000 to 25,000 children are born in the United States each year to mothers with epilepsy, and between 0.3% and 0.5% of all pregnancies occur among women with epilepsy. Most of these women need to continue taking medication during pregnancy because uncontrolled convulsive seizures may be harmful to the women as well as to their fetuses. The challenge to physicians is to prescribe a treatment that is effective in controlling seizures but has minimal associated risks.

Overall, 95% of women with epilepsy have uncomplicated pregnancies and deliver normal babies. This rate can be significantly improved with proper management; any serious harm to the baby or mother, particularly if it is avoidable, is too much for the family that is affected. The highest risks for major congenital malformations and adverse cognitive outcomes are associated with polytherapy (mainly combination of valproate and lamotrigine). With monotherapy, the highest risk is found with valproate followed by topiramate. In utero exposure to monotherapy with lamotrigine, carbamazepine, and levetiracetam have a low risk of major congenital malformations, near 2.5%. Furthermore, the concentration of antiepileptic drugs may change significantly during pregnancy and the puerperium, resulting in an increase in seizures (mainly with lamotrigine and oxcarbazepine) or toxicity. Women should be made fully aware of all aspects of antiepileptic drug treatment and be able to make informed decisions.

In this article, Dr. C P Panayiotopoulos of St. Thomas’ Hospital details the various issues that women with epilepsy face before, during, and after pregnancy.

To view the complete article, click here and log in.

Twitter Digest for January 19, 2018

Twitter Digest for January 18, 2018

Spotlight on CLIPPERS

In this article, Dr. Morten Blaabjerg of Odense University and Dr. Daniel Kondziella of Copenhagen University Hospital discuss chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). CLIPPERS is an inflammatory condition of unknown etiology, primarily involving the brainstem and cerebellum. Symptoms of CLIPPERS include subacute onset of brainstem symptoms–most prominently, ataxia, diplopia, dysarthria, and altered facial sensation. The core radiological features are punctate or curvilinear perivascular gadolinium enhancement, typically in the pons and adjacent cerebellum. Neuropathological examination of affected areas reveals a perivascular lymphocytic inflammation with predominant CD4+ T cells. Clinical and radiological features respond to high-dose corticosteroid treatment, but continuous oral corticosteroid treatment and steroid-sparing agents are needed to prevent relapses and to reduce the risk for subsequent parenchymal atrophy and chronic ataxia. The differential diagnosis for CLIPPERS is broad, and a careful workup is needed.

To view the complete article, click here and log in.

Twitter Digest for January 17, 2018

Twitter Digest for January 16, 2018